“As a medium-sized, foreign-based pharma firm, we rely heavily on the Tufts Center for the Study of Drug Development for its scholarly research reports on drug development trends to help us assess our own performance and to understand the current regulatory environment. In addition, many of our employees have greatly benefited from taking the Tufts Center's highly regarded clinical pharmacology and drug development training courses. The Tufts Center is an invaluable resource.”
Joseph P. Pieroni
President and Chief Executive Officer
Daiichi Sankyo, Inc.

“As the leader of a large R&D organization in the pharmaceutical industry, I rely heavily on the objective industry benchmarking and performance metrics generated by the Tufts Center for the Study of Drug Development. This information is critical for assessing our own performance and targeting important areas for growth and improvement. The high quality and unbiased work of the Tufts Center is essential to our organization.”
Robert R. Ruffolo, Jr., Ph.D.
President, Research & Development
Wyeth Pharmaceuticals

“The Tufts Center for the Study of Drug Development has a well-deserved international reputation for scholarly analyses and timely reports on the nature and pace of new drug development. The data generated by the Tufts Center are vital to us in our efforts to improve R&D performance and yield. Moreover, the work of the Tufts Center has been enormously influential in political and regulatory debates worldwide on issues related to pharmaceutical innovation.”
John C. Lechleiter
President and Chief Operating Officer
Eli Lilly and Company

Back